Mechanism of human antibody-mediated neutralization of Marburg virus.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25723164.
- Also identified by DOI 10.1016/j.cell.2015.01.031 and PMC identifier 4344968.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The mechanisms by which neutralizing antibodies inhibit Marburg virus (MARV) are not known. We isolated a panel of neutralizing antibodies from a human MARV survivor that bind to MARV glycoprotein (GP) and compete for binding to a single major antigenic site. Remarkably, several of the antibodies also bind to Ebola virus (EBOV) GP. Single-particle EM structures of antibody-GP complexes reveal that all of the neutralizing antibodies bind to MARV GP at or near the predicted region of the receptor-binding site. The presence of the glycan cap or mucin-like domain blocks binding of neutralizing antibodies to EBOV GP, but not to MARV GP. The data suggest that MARV-neutralizing antibodies inhibit virus by binding to infectious virions at the exposed MARV receptor-binding site, revealing a mechanism of filovirus inhibition.
Medical subject headings
- Antibodies, Neutralizing
- Antigen-Antibody Complex
- Marburg Virus Disease
- Marburgvirus
- Viral Envelope Proteins